Market closed
Akebia Therapeutics/$AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
181
Website
AKBA Metrics
BasicAdvanced
$640M
-
-$0.33
0.94
-
Price and volume
Market cap
$640M
Beta
0.94
52-week high
$2.89
52-week low
$0.80
Average daily volume
4.2M
Financial strength
Current ratio
1.407
Quick ratio
1.066
Long term debt to equity
-363.965
Total debt to equity
-383.713
Interest coverage (TTM)
-2.54%
Management effectiveness
Return on assets (TTM)
-12.49%
Return on equity (TTM)
174.03%
Valuation
Price to revenue (TTM)
3.213
Price to book
-11.2
Price to tangible book (TTM)
-5.09
Price to free cash flow (TTM)
-12.649
Growth
Revenue change (TTM)
-17.70%
Earnings per share change (TTM)
18.79%
3-year revenue growth (CAGR)
-8.87%
3-year earnings per share growth (CAGR)
-42.15%
What the Analysts think about AKBA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
AKBA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AKBA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AKBA News
AllArticlesVideos
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
GlobeNewsWire·3 days ago
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
GlobeNewsWire·1 month ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $640M as of May 04, 2025.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of May 04, 2025.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of May 04, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.